

# Hugo Arasanż

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/879759/publications.pdf>

Version: 2024-02-01

25  
papers

1,360  
citations

567144

15  
h-index

552653

26  
g-index

31  
all docs

31  
docs citations

31  
times ranked

2124  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical landscape of LAG-3-targeted therapy. <i>Immuno-Oncology Technology</i> , 2022, 14, 100079.	0.2	37
2	CAR-T Cells for the Treatment of Lung Cancer. <i>Life</i> , 2022, 12, 561.	1.1	8
3	The multi-specific VH-based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity. <i>British Journal of Cancer</i> , 2022, 126, 1168-1177.	2.9	9
4	Hyperprogressive Disease: Main Features and Key Controversies. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3736.	1.8	18
5	Understanding LAG-3 Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5282.	1.8	78
6	A Proteomic Atlas of Lineage and Cancer-Polarized Expression Modules in Myeloid Cells Modeling Immunosuppressive Tumor-Infiltrating Subsets. <i>Journal of Personalized Medicine</i> , 2021, 11, 542.	1.1	6
7	Systemic CD4 Immunity as a Key Contributor to PD-L1/PD-1 Blockade Immunotherapy Efficacy. <i>Frontiers in Immunology</i> , 2020, 11, 586907.	2.2	40
8	Profound Reprogramming towards Stemness in Pancreatic Cancer Cells as Adaptation to AKT Inhibition. <i>Cancers</i> , 2020, 12, 2181.	1.7	9
9	PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5918.	1.8	15
10	Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics. <i>Cancers</i> , 2020, 12, 344.	1.7	60
11	Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?. <i>Frontiers in Pharmacology</i> , 2020, 11, 441.	1.6	48
12	Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2411.	1.8	28
13	Systemic CD4 immunity: A powerful clinical biomarker for PD-L1/PD-1 immunotherapy. <i>EMBO Molecular Medicine</i> , 2020, 12, e12706.	3.3	19
14	Functional systemic CD4 immunity is required for clinical responses to PD-L1/CD4 blockade therapy. <i>EMBO Molecular Medicine</i> , 2019, 11, e10293.	3.3	145
15	PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1631.	1.8	59
16	Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO <sub>2</sub> Chromatography. <i>Journal of Proteome Research</i> , 2018, 17, 1172-1182.	1.8	21
17	Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 113-123.	1.0	36
18	Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies. <i>Lung Cancer Management</i> , 2018, 7, LMT07.	1.5	1

#	ARTICLE	IF	CITATIONS
19	The intracellular signalosome of PD-L1 in cancer cells. <i>Signal Transduction and Targeted Therapy</i> , 2018, 3, 26.	7.1	174
20	Immunotherapy in malignant melanoma: recent approaches and new perspectives. <i>Melanoma Management</i> , 2017, 4, 39-48.	0.1	7
21	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. <i>Cell Reports</i> , 2017, 20, 1818-1829.	2.9	220
22	PD1 signal transduction pathways in T cells. <i>Oncotarget</i> , 2017, 8, 51936-51945.	0.8	191
23	Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy. <i>Annals of Translational Medicine</i> , 2017, 5, 385-385.	0.7	50
24	Novel immunotherapies for the treatment of melanoma. <i>Immunotherapy</i> , 2016, 8, 613-632.	1.0	5
25	A core of kinase-regulated interactomes defines the neoplastic MDSC lineage. <i>Oncotarget</i> , 2015, 6, 27160-27175.	0.8	51